Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,590,223
  • Shares Outstanding, K 58,314
  • Annual Sales, $ 36,500 K
  • Annual Income, $ 673,730 K
  • EBIT $ -476 M
  • EBITDA $ -484 M
  • 60-Month Beta 0.87
  • Price/Sales 43.87
  • Price/Cash Flow N/A
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 65.16% (-0.14%)
  • Historical Volatility 211.83%
  • IV Percentile 61%
  • IV Rank 12.31%
  • IV High 254.54% on 11/18/25
  • IV Low 38.58% on 05/21/25
  • Expected Move (DTE 5) 2.21 (8.10%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 838
  • Volume Avg (30-Day) 6,096
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 89,839
  • Open Int (30-Day) 75,985
  • Expected Range 25.06 to 29.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.96
  • Number of Estimates 6
  • High Estimate -1.80
  • Low Estimate -2.09
  • Prior Year -1.74
  • Growth Rate Est. (year over year) -12.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.24 +22.62%
on 11/19/25
46.00 -40.72%
on 11/18/25
-16.36 (-37.50%)
since 11/12/25
3-Month
22.24 +22.62%
on 11/19/25
46.00 -40.72%
on 11/18/25
-9.51 (-25.86%)
since 09/12/25
52-Week
22.24 +22.62%
on 11/19/25
46.00 -40.72%
on 11/18/25
-10.90 (-28.56%)
since 12/12/24

Most Recent Stories

More News
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.27 (-0.69%)
Stocks Settle Higher Before Nvidia Earnings

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.56%. December...

MSTR : 176.45 (-3.74%)
MPC : 185.77 (-0.72%)
GOOGL : 309.29 (-1.01%)
GTLB : 39.52 (-2.90%)
ADI : 279.32 (-1.44%)
COIN : 267.46 (-0.58%)
OXY : 41.07 (-0.32%)
DY : 345.78 (-5.14%)
^BTCUSD : 88,218.94 (-2.23%)
SPY : 681.76 (-1.08%)
QS : 11.80 (-7.74%)
MP : 56.66 (-5.58%)
Stocks Supported by Strength in Megacap Tech and Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.74%. December E-mini S&P...

AMAT : 259.21 (-4.04%)
MPC : 185.77 (-0.72%)
GOOGL : 309.29 (-1.01%)
GTLB : 39.52 (-2.90%)
AVGO : 359.93 (-11.43%)
CVX : 149.99 (-0.48%)
IRM : 83.35 (-5.32%)
ADI : 279.32 (-1.44%)
$IUXX : 25,196.73 (-1.91%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-080 (+0.07%)
OXY : 41.07 (-0.32%)
Stock Indexes Gain on Strength in Alphabet and Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.60%. December E-mini S&P futures...

AMAT : 259.21 (-4.04%)
MPC : 185.77 (-0.72%)
GOOGL : 309.29 (-1.01%)
GTLB : 39.52 (-2.90%)
CVX : 149.99 (-0.48%)
$IUXX : 25,196.73 (-1.91%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-080 (+0.07%)
OXY : 41.07 (-0.32%)
AGIO : 27.27 (-0.69%)
ESZ25 : 6,830.75 (unch)
FANG : 156.68 (-0.23%)
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did...

AGIO : 27.27 (-0.69%)
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.27 (-0.69%)
Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Pharmaceuticals: Q3 Earnings Snapshot

AGIO : 27.27 (-0.69%)
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

$12.9 million in third quarter PYRUKYND ® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia;...

AGIO : 27.27 (-0.69%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).  Such investors are...

AGIO : 27.27 (-0.69%)
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.27 (-0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 28.58
2nd Resistance Point 28.12
1st Resistance Point 27.70
Last Price 27.27
1st Support Level 26.81
2nd Support Level 26.35
3rd Support Level 25.93

See More

52-Week High 46.00
Fibonacci 61.8% 36.92
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
Last Price 27.27
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar